Prefer to read in print? Subscribe for free here
If you would like to feature in the next issue of Pf Magazine, contact us here
Latest articles
Antibiotic Research UK launches small research grants programme
Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
New COVID-19 test reduces testing time from 30 minutes to five
University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...